Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mural Oncology Plc (MURA)
NASDAQ:MURA
Holding MURA?
Track your performance easily
MURA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.87 - $6.25
Previous Close$3.14
Volume207.56K
Average Volume (3M)152.17K
Market Cap
$53.57M
Enterprise Value-$112.38M
Total Cash (Recent Filing)$175.50M
Total Debt (Recent Filing)$9.55M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Apr 01, 2025EPS Estimate
-$2.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.14
Shares Outstanding17,060,310
10 Day Avg. Volume293,090
30 Day Avg. Volume152,170
Standard Deviation0.24
R-Squared0.18
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.31
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.83
Forecast
1Y Price Target
$16.33Price Target Upside413.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Mural Oncology Plc News
PremiumStock Analysis & Ideas
Raymond James Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks
PremiumCompany Announcements
Mural Oncology’s Investor Day Highlights Cancer Treatment TrialsOwnership Overview
2.53% Insiders
7.33% Mutual Funds
35.45% Other Institutional Investors
49.72% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MURA FAQ
What was Mural Oncology Plc’s price range in the past 12 months?
Mural Oncology Plc lowest stock price was $2.87 and its highest was $6.25 in the past 12 months.
What is Mural Oncology Plc’s market cap?
Currently, no data Available
When is Mural Oncology Plc’s upcoming earnings report date?
Mural Oncology Plc’s upcoming earnings report date is Apr 01, 2025 which is in 100 days.
How were Mural Oncology Plc’s earnings last quarter?
Mural Oncology Plc released its earnings results on Nov 13, 2024. The company reported -$1.87 earnings per share for the quarter, beating the consensus estimate of -$1.972 by $0.102.
Is Mural Oncology Plc overvalued?
According to Wall Street analysts Mural Oncology Plc’s price is currently Undervalued.
Does Mural Oncology Plc pay dividends?
Mural Oncology Plc does not currently pay dividends.
What is Mural Oncology Plc’s EPS estimate?
Mural Oncology Plc’s EPS estimate is -$2.01.
How many shares outstanding does Mural Oncology Plc have?
Mural Oncology Plc has 17,060,310 shares outstanding.
What happened to Mural Oncology Plc’s price movement after its last earnings report?
Mural Oncology Plc reported an EPS of -$1.87 in its last earnings report, beating expectations of -$1.972. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mural Oncology Plc?
Among the largest hedge funds holding Mural Oncology Plc’s share is PRIMECAP Management Co. It holds Mural Oncology Plc’s shares valued at 438K.
---
Mural Oncology Plc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.33 (413.52% Upside)
$16.33 (413.52% Upside)
Blogger Sentiment
Bullish
MURA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 95.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.5%
Last 30 Days ▲ 848.8%
Last 30 Days ▲ 848.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.28%
12-Months-Change
Fundamentals
Return on Equity
-183.89%
Trailing 12-Months
Asset Growth
573.05%
Trailing 12-Months
Company Description
Mural Oncology Plc
Mural Oncology¿s pipeline is built to address difficult-to-treat tumor types where checkpoint inhibitors are not effective. The Company¿s lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational, engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 (rhIL-2), while mitigating the hallmark toxicities of native IL-2 in difficult-to-treat cancers with high unmet need. Nemvaleukin is currently in two potentially registrational studies: one for the treatment of mucosal melanoma as a monotherapy and one for the treatment of platinum-resistant ovarian cancer (PROC) in combination with pembrolizumab.
---
MURA Stock 12 Month Forecast
Average Price Target
$16.33
▲(413.52% Upside)
Technical Analysis
Best Analysts Covering MURA
1 Year
1 Year Success Rate
2/4 ratings generated profit
1 Year Average Return
-8.85%
reiterated a buy rating last month
Copying Judah Frommer's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -8.85% per trade.
---